Results 281 to 290 of about 218,137 (295)

Clinicopathological analysis of programmed cell death 1 and programmed cell death ligand 1 expression in the tumour microenvironments of diffuse large B cell lymphomas

Histopathology, 2016
Dohee Kwon, Sehui Kim, Heounjeong Go
exaly  

Programmed Death-1/Programmed Death Ligand-1 Inhibitor–Related Pneumonitis and Radiographic Patterns

Journal of Clinical Oncology, 2017
Mizuki, Nishino, Hiroto, Hatabu
openaire   +2 more sources

EML4-ALK enhances programmed cell death-ligand 1 expression in pulmonary adenocarcinoma via hypoxia-inducible factor (HIF)-1α and STAT3

OncoImmunology, 2016
Jaemoon Koh, Bhumsuk Keam, Sehui Kim
exaly  

Clinicopathologic and Prognostic Implications of Programmed Death Ligand 1 Expression in Thymoma

Annals of Thoracic Surgery, 2016
Shintaro Yokoyama, Hiroaki Miyoshi, Tatsuya Nishi   +2 more
exaly  

Programmed death-ligand 1 and survival in colorectal cancers: A meta-analysis

International Journal of Biological Markers, 2019
Yugang Wu
exaly  

Expression of programmed death-1 (PD-1) and its ligand PD-L1 is upregulated in endometriosis and promoted by 17beta-estradiol

Gynecological Endocrinology, 2019
Mingjiang Li
exaly  

The Combination of MEK Inhibitor With Immunomodulatory Antibodies Targeting Programmed Death 1 and Programmed Death Ligand 1 Results in Prolonged Survival in Kras/p53-Driven Lung Cancer

Journal of Thoracic Oncology, 2019
Jong Woo Lee, Kyung Jin Eoh, Miguel F Sanmamed   +2 more
exaly  

Serum levels of soluble programmed death‐1 and programmed death ligand‐1 in systemic sclerosis: Association with extent of skin sclerosis

Journal of Dermatology, 2016
Koichi Yanaba, Mitsuha Hayashi, Yuki Yoshihara   +2 more
exaly  

Tumour‐infiltrating lymphocytes and expression of programmed death ligand 1 (PD‐L1) in melanoma brain metastases

Histopathology, 2015
Anna S Berghoff, Gerda Ricken, Georg Widhalm   +2 more
exaly  

Programmed death ligand‐1 expression is associated with poor disease free survival in salivary gland carcinomas

Journal of Surgical Oncology, 2016
Toru Ugumori, Satoshi Fujii
exaly